Natera Q4 2016 Revenues Drop 7 Percent

Mar 08, 2017

NEW YORK (GenomeWeb) – Natera's fourth quarter 2016 revenues fell 7 percent compared to the fourth quarter of 2015, the firm reported after the close of the market on Tuesday.

The San Carlos, California-based molecular diagnostics company reported total revenues of $49.3 million for the three months ended Dec. 31, 2016, compared to $52.9 million in Q4 2015. Its Q4 2016 revenue was slightly below the analysts' average estimate of $49.8 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Featured White Papers

Effective Miniaturization of Illumina Nextera XT Library Prep for Multiplexed Whole Genome Sequencing and Microbiome Applications

Jan

30

Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS Approaches for Microbiome Studies

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Feb

14

Featured Webinar

Transcriptome of an Agricultural Pest Delineated by Oxford Nanopore RNA-Seq

This webinar will describe a project that applied Oxford Nanopore long-read RNA-seq to explore the transcriptional landscape of a damaging agricultural pest.

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb

26

Featured Webinar

A Cellular and Molecular Phenotyping Pipeline for Target Characterization in FFPE Biobank Samples

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.

Main menu